AAVANTGARDE

AAVANTGARDE BIO Srl is a clinical-stage international biotechnology company headquartered in Italy. The company has developed two proprietary adeno-associated virus (AAV) vector platforms to address the gene therapy cargo capacity limitations of AAV vectors. The AAVANTGARDE platform can be used to deliver large genes to ocular and non-ocular tissues. Founded by Professor Alberto Auricchio of TIGEM (Telethon Institute of Genetics and Medicine) in Naples, Italy, and the Telethon Foundation, the platform will initially be validated in clinical trials for two inherited retinal diseases with significant unmet needs.